Asthma and COPD added to CAI's Cellular Disease Models, Aug 29, 2016
To facilitate research and airway drug development, Cell Applications now offers a panel of primary cells for use in Asthma and COPD studies. The cells, isolated from donors afflicted by the diseases, include Bronchial & Tracheal Epithelial Cells, Pulmonary & Lung Microvascular Endothelial cells and others. Multiple donor profiles and lots are available. Asthma and Chronic Obstructive Pulmonary Disease are both long-term diseases, where genetic, environmental and lifestyle factors cause the lungs and airways to deliver poor air flow. ?The resulting shortness of breath can be life-threatening in severe or end-stage cases,? says Dr. Daniel Schroen, Vice President of Sales and Marketing at Cell Application. ?There?s no cure for either, and asthma often begins in early childhood. We want to help life science researchers and pharmaceutical companies make strides in understanding, treating and managing the diseases.?
Cell Applications, Inc. Launches Human Dendritic Cells and Media, Aug 26, 2016
Today CAI introduced Human Dendritic Cells to their primary Blood Cell portfolio. Isolated from peripheral blood, the cells (HDC-PB for short) arise from a distinct hematopoietic lineage and help regulate the immune system. They mount adaptive immune responses to foreign antigens, prime T cells through antigen presentation and can induce tolerance to self-antigens. Academic & industrial research is driving toward new therapeutic approaches to modulate dendritic cells for vaccines and therapies to suppress pathogens, tumors and autoimmune disorders. According to Daniel Schroen, Vice President Sales and Marketing, ?Dendritic Cells complement and extend our other blood-derived cells, like T & B Lymphocytes, Hematopoietic Stem Cells, Mononuclear Cells, Monocytes, Macrophages and Microglial Cells.? Immunologists and others who study blood disorders can now source most blood cell types and media from one place. In addition to simplifying orders, lab workers can also benefit from the consistency of single-source products. ?That uniformity can improve the soundness of data comparing multiple cell types, for instance,? added Schroen. Currently undergoing an expansion phase, Cell Applications plans additional new primary cell products and services over the remainder of the year and into early 2017.
Daniel Schroen, PhD
Vice President, Sales & Marketing
Cell Applications, Inc.
5820 Oberlin Dr, Suite 101
San Diego, CA 92121
858.453.0848 (M 760.717.6055)